Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.30
Bid: 3.20
Ask: 3.40
Change: 0.00 (0.00%)
Spread: 0.20 (6.25%)
Open: 3.30
High: 3.30
Low: 3.30
Prev. Close: 3.30
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Arecor Therapeutics wins patent approval in US

Wed, 23rd Mar 2022 20:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hydrogen Utopia International PLC - London-based company specialising in turning non-recyclable mixed waste plastic into carbon-free fuels - Says it believes that building new waste plastic to energy plants could be "significant" in allowing local communities across Europe to lessen the impacts of the gas and energy supply crisis and the anticipated market changes brought about by ongoing sanctions against Russia and the reluctance to rely upon it as an energy supplier in the future.

----------

ValiRx PLC - Nuneaton, England-based drug development company - Reports it is progressing towards the completion of its proposed sub-licence of VAL201 to TheoremRx Inc. VAL201's primary indication is for prostate cancer, with potential further research & development in breast and ovarian cancer. Company says TheoremRx continues to make good progress with its financing but notes that current global macro-economic events have impacted the timelines. First payments to ValiRx are expected on or before the end of June.

----------

Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Wins patent grant from US Patent & Trademark Office protecting novel formulations of the group's insulin products, AT247 and AT278. Chief Scientific Officer Jan Jezek says: "This recently granted US patent, the first within the group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress."

----------

GENinCode PLC - Manchester-based genetic testing company - Collaborates with Indiana University School of Medicine on a study using its Cardio inCode-SCORE for the risk assessment of patients for onset of atherosclerotic cardiovascular disease.

----------

88 Energy Ltd - oil exploration company focused on Alaska - Reaches total depth of 7,334 feet at Merlin-2 well and ceases drilling. Company says all three target reservoirs at the well were penetrated with elevated gas readings. Adds observations of cutting samples have revealed oil shows over all targets. Wireline logging is due to commence shortly.

----------

i(x) Net Zero PLC - Jersey-based investment company focused on sustainability - Says portfolio company Context Labs has secures a multi-year partnership with energy company Williams Co Inc. Partnership for the deployment of its Immutably-based Decarbonization as a Service platform. The deployment of the enterprise data fabric solution will facilitate Williams' energy transition, i(x) explains.

----------

All Star Minerals PLC - Haywards Heath, England-based mining services investor - Appoints Jason Brewer as chief executive officer. Current CEO Ian Harebottle reverts to the position of non-executive director with immediate effect. Says restructuring has been driven by "recent developments in Europe".

----------

Panther Metals PLC - mineral exploration company focused on Canada - Notes announcement of Panther Metals Ltd, in which it has 37% holding, detailing "significant" reverse circulation drilling sample assay results. Results from the Coglia nickel cobalt project in Western Australia include: 21 metres at 1.34% nickel from 72 metres and 10 metres at 1.3% nickel from 62 metres. 18 of the 26 holes assayed return results above 0.5% nickel and 500 parts per million of copper. Once drilling is complete at Coglia the drill rig will move to the Eight Foot Well gold prospect, the company adds.

----------

Cohort PLC - Reading, England-based technology company - Says its German subsidiary ELAC Sonar has been awarded a contract to supply hydroacoustic equipment by Fassmer Shipyard, on behalf of the Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support. Contract is worth EUR4 million and is expected to complete in the final quarter of 2023.

----------

Tern PLC - London-based investor focused on the internet of things - Notes that Wyld Networks AB has received a purchase order for its Wyld Connect internet of things module from an unnamed Brazilian company in the forestry sector. Tern holds 59% of Wyld Networks.

----------

Capital Metals PLC - London-based mineral sands explorer - Says IHC Mining is nearing the completion of the development study for the Eastern Minerals project in Sri Lanka. Capital Metals expects the final report by mid-April. Adds that drill samples from the project are continuing to be assayed by an independent laboratory but warns of backlogs. Company working with Sri Lankan government to secure industrial mining license but says timeline is beyond their control. Discussion regarding offtake and strategic party agreements continue.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
10 Feb 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Jan 2020 14:50

ValiRx signs letter of intent in a bid to fund VAL401

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

Read more
14 Jan 2020 11:08

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

Read more
6 Jan 2020 09:59

ValiRx Raises GBP200,000 To Progress Product Development

ValiRx Raises GBP200,000 To Progress Product Development

Read more
16 Dec 2019 10:17

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

Read more
28 Nov 2019 16:13

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

Read more
28 Nov 2019 15:57

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

Read more
14 Oct 2019 13:44

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

Read more
26 Sep 2019 11:43

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

Read more
24 Sep 2019 12:40

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

Read more
10 Sep 2019 13:45

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

Read more
1 Aug 2019 12:01

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

Read more
23 Jul 2019 16:25

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

Read more
26 Jun 2019 14:30

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

Read more
26 Jun 2019 10:53

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.